DK0648117T3 - Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser - Google Patents

Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser

Info

Publication number
DK0648117T3
DK0648117T3 DK93912628.0T DK93912628T DK0648117T3 DK 0648117 T3 DK0648117 T3 DK 0648117T3 DK 93912628 T DK93912628 T DK 93912628T DK 0648117 T3 DK0648117 T3 DK 0648117T3
Authority
DK
Denmark
Prior art keywords
binding active
pct
tolerance
drug
treatment
Prior art date
Application number
DK93912628.0T
Other languages
English (en)
Inventor
Herbert Schneider
Lechoslaw Turski
David Norman Stephens
Karin Gabriele Steppuhn
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK0648117T3 publication Critical patent/DK0648117T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93912628.0T 1992-07-09 1993-06-22 Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser DK0648117T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4222826A DE4222826A1 (de) 1992-07-09 1992-07-09 Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen

Publications (1)

Publication Number Publication Date
DK0648117T3 true DK0648117T3 (da) 1998-02-23

Family

ID=6462983

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93912628.0T DK0648117T3 (da) 1992-07-09 1993-06-22 Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser

Country Status (10)

Country Link
US (1) US5614509A (da)
EP (1) EP0648117B1 (da)
JP (1) JPH07508734A (da)
AT (1) ATE155683T1 (da)
CA (1) CA2139488A1 (da)
DE (2) DE4222826A1 (da)
DK (1) DK0648117T3 (da)
ES (1) ES2107032T3 (da)
GR (1) GR3024854T3 (da)
WO (1) WO1994001094A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696922B2 (en) 1993-04-20 1998-09-24 Merck & Co., Inc. Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック， エルエルシー Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
DE59209162D1 (de) * 1991-07-05 1998-03-05 Asta Medica Ag Verwendung von Schwefel enthaltenden Carbonsäuren zur Bekämpfung von pathophysiologisch bedingten Erregungsstörungen
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen

Also Published As

Publication number Publication date
DE59306983D1 (de) 1997-08-28
JPH07508734A (ja) 1995-09-28
DE4222826A1 (de) 1994-01-13
EP0648117B1 (de) 1997-07-23
US5614509A (en) 1997-03-25
WO1994001094A1 (de) 1994-01-20
EP0648117A1 (de) 1995-04-19
ATE155683T1 (de) 1997-08-15
ES2107032T3 (es) 1997-11-16
CA2139488A1 (en) 1994-01-20
GR3024854T3 (en) 1998-01-30

Similar Documents

Publication Publication Date Title
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
ES2121793T3 (es) Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
ES2091689T3 (es) Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
ATE259815T1 (de) Neue antagonistische verbindungen
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ID23799A (id) Penggunaan antagonis reseptor 5ht2 spesifik untuk pembuatan obat obatan yang berguna dalam pengobatan sindrom apnea saat tidur
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE201686T1 (de) Imidazo(1,2-a)indeno(1,2-e)pyrazin-4-onderivate und diese enthaltende pharmazeutische zubereitungen
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
DK0656002T3 (da) 3-Oxo-pyrido(1,2-a)benzimidazol-4-carboxyl- og 4-oxo-azepino(1,2-a)benzimidazol-5-carboxylderivater, som er anvendelige ved
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
EE03385B1 (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
NO950177D0 (no) Farmakologisk aktive erivater
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
ZA9427B (en) Use of riluzole for promoting restoration following radiation
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it